Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor

Kennedy, Laura C.; Lü, Jun; Kuehn, Sydney; Ramirez, Arturo B.; Lo, Edward Chin Man; Sun, Yao; U'Ren, Lance; Chow, Laura Q.; Grivas, Petros; Kaldjian, Eric P.; Gadi, Vijayakrishna K.

doi:10.1007/s11523-022-00891-0

Cited by 3 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have utilized the AccuCyte-CyteFinder platform to detect CTCs in various cancers such as prostate, breast, and lung ( 9 , 10 , 26 , 28 , 29 , 31 – 33 ). This study is the first to examine CTCs using this platform in thyroid cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Additional biomarkers may also be relevant to a specific tumor subtype, provide prognostic value, or to facilitate patient selection for targeted therapies. For example, PD-L1 for monitoring patients undergoing immunotherapy ( 10 ), androgen receptor splice variant 7 (ARv7) for emergence of therapeutic resistance in prostate cancer ( 31 ), and assessing biomarkers such as EGFR, HER2 or PD-L1 in esophageal cancer ( 36 ). Furthermore, the platform has a single-cell retrieval device, CellPicker™, where identified cells can be picked for single-cell molecular characterization.…”

Section: Discussionmentioning

confidence: 99%

“…CTCs are a potential biomarker for screening high-risk populations and for evaluating disease recurrence and metastatic spread. Early detection may provide the opportunity for initiating early treatment and thus, optimizing patient management (6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionThe reliable and accurate detection of rare circulating tumor cells (CTCs) from cancer patient blood samples promises advantages in both research and clinical applications. Numerous CTC detection methods have been explored that rely on either the physical properties of CTCs such as density, size, charge, and/or their antigen expression profiles. Multiple factors can influence CTC recovery including blood processing method and time to processing. This study aimed to examine the accuracy and sensitivity of an enrichment-free method of isolating leukocytes (AccuCyte® system) followed by immunofluorescence staining and high-resolution imaging (CyteFinder® instrument) to detect CTCs.MethodHealthy human blood samples, spiked with cancer cells from cancer cell lines, as well as blood samples obtained from 4 subjects diagnosed with cancer (2 pancreatic, 1 thyroid, and 1 small cell lung) were processed using the AccuCyte-CyteFinder system to assess recovery rate, accuracy, and reliability over a range of processing times.ResultsThe AccuCyte-CyteFinder system was highly accurate (95.0%) at identifying cancer cells in spiked-in samples (in 7.5 mL of blood), even at low spiked-in numbers of 5 cells with high sensitivity (90%). The AccuCyte-CyteFinder recovery rate (90.9%) was significantly higher compared to recovery rates obtained by density gradient centrifugation (20.0%) and red blood cell lysis (52.0%). Reliable and comparable recovery was observed in spiked-in samples and in clinical blood samples processed up to 72 hours post-collection. Reviewer analysis of images from spiked-in and clinical samples resulted in high concordance (R-squared value of 0.998 and 0.984 respectively).DiscussionThe AccuCyte-CyteFinder system is as an accurate, sensitive, and clinically practical method to detect and enumerate cancer cells. This system addresses some of the practical logistical challenges in incorporating CTCs as part of routine clinical care. This could facilitate the clinical use of CTCs in guiding precision, personalized medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, the study of these critical immune and inflammatory genes is important not only in liver cancer but also in other cancer types, and the detection of biomarkers associated with these genes can aid in treatment decision making for a wide range of cancer patients. [ 171 ].…”

Section: Genes Associated With Nivolumab and Pembrolizumab Resistancementioning

confidence: 99%

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Huang

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

Liver cancer is one of the most lethal cancers in the world, mainly owing to the lack of effective means for early monitoring and treatment. Accordingly, there is considerable research interest in various clinically applicable methods for addressing these unmet needs. At present, the most commonly used biomarker for the early diagnosis of liver cancer is alpha-fetoprotein (AFP), but AFP is sensitive to interference from other factors and cannot really be used as the basis for determining liver cancer. Treatment options in addition to liver surgery (resection, transplantation) include radiation therapy, chemotherapy, and targeted therapy. However, even more expensive targeted drug therapies have a limited impact on the clinical outcome of liver cancer. One of the big reasons is the rapid emergence of drug resistance. Therefore, in addition to finding effective biomarkers for early diagnosis, an important focus of current discussions is on how to effectively adjust and select drug strategies and guidelines for the treatment of liver cancer patients. In this review, we bring this thought process to the drug resistance problem faced by different treatment strategies, approaching it from the perspective of gene expression and molecular biology and the possibility of finding effective solutions.

show abstract

Recent developments in immunotherapy for gastrointestinal tract cancers

Chong,

Madeti,

Cai

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor

Cited by 3 publications

References 35 publications

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Recent developments in immunotherapy for gastrointestinal tract cancers

Contact Info

Product

Resources

About